2/25
09:52 am
rdy
Zydus to launch generic semaglutide injections in India after patent expiry in March [Yahoo! Finance]
Low
Report
Zydus to launch generic semaglutide injections in India after patent expiry in March [Yahoo! Finance]
2/20
10:57 am
rdy
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
Low
Report
Dr. Reddy’s Announces USFDA Acceptance to Review Its Biologics License Application (BLA) for Proposed Interchangeable Biosimilar, Abatacept
2/17
08:03 am
rdy
Dr Reddy's aims to launch generic obesity drug at 60% discount [Yahoo! Finance]
Low
Report
Dr Reddy's aims to launch generic obesity drug at 60% discount [Yahoo! Finance]
2/15
06:32 am
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
2/1
06:31 am
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was upgraded by analysts at
Weiss Ratings from a "hold (c+)" rating to a "buy (b-)" rating.
1/30
08:51 am
rdy
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
Low
Report
Coya Therapeutics raises $11.1M in private placement led by Dr. Reddy's [Seeking Alpha]
1/25
08:31 pm
rdy
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
Low
Report
Dr Reddy's Laboratories Ltd (RDY) Q3 2026 Earnings Call Highlights: Navigating Growth Amidst ... [Yahoo! Finance]
1/21
11:41 pm
rdy
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
Low
Report
Dr. Reddy's GAAP EPS of ?14.52, revenue of ?87.27B [Seeking Alpha]
1/21
04:27 pm
rdy
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
Low
Report
Dr. Reddy's Laboratories Limited (RDY) Q3 2026 Earnings Call Transcript [Seeking Alpha]
1/21
12:41 pm
rdy
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
Low
Report
Dr. Reddy's Laboratories Q3 Earnings Call Highlights [Yahoo! Finance]
1/17
04:31 pm
rdy
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
Low
Report
Dr. Reddy's Laboratories (NYSE:RDY) was downgraded by analysts at
Weiss Ratings from a "buy (b-)" rating to a "hold (c+)" rating.
1/14
08:49 am
rdy
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Low
Report
Dr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
12/2
08:00 am
rdy
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
Low
Report
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies